Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a rare progressive neurodegenerative disorder caused by mutations in CLN3. Patients present with early-onset retinal degeneration, followed by epilepsy, progressive motor deficits, cognitive decline, and premature death. Approximately 85% of individuals with Batten disease harbor at least one allele containing a 1.02 kb genomic deletion spanning exons 7 and 8. This study demonstrates CRISPR-Cas9-based homology-dependent repair of this mutation in induced pluripotent stem cells generated from two independent patients: one homozygous and one compound heterozygous for the 1.02 kb deletion. Our strategy included delivery of a construct that carried >3 kb of DNA: wild-type CLN3 sequence and a LoxP-flanked, puromycin resistance cassette for positive selection. This strategy resulted in correction at the genomic DNA and mRNA levels in the two independent patient lines. These CRISPR-corrected isogenic cell lines will be a valuable tool for disease modeling and autologous retinal cell replacement.
Get full access to this article
View all access options for this article.
References
1.
PhillipsSN, BenedictJW, WeimerJM, et al.CLN3, the protein associated with Batten disease: structure, function and localization. J Neurosci Res, 2005; 79:573–583. DOI:10.1002/jnr.20367.
2.
EzakiJ, Takeda-EzakiM, KoikeM, et al.Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. J Neurochem, 2003; 87: 1296–1308. DOI:10.1046/j.1471-4159.2003.02132.x.
3.
KyttäläA, IhrkeG, VesaJ, et al.Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol Biol Cell, 2004; 15:1313–1323. DOI:10.1091/mbc.E03-02-0120.
4.
MaoQ, FosterBJ, XiaH, et al.Membrane topology of CLN3, the protein underlying Batten disease. FEBS Lett, 2003; 541:40–46. DOI:10.1016/S0014-5793(03)00284-9.
5.
MaoQ, XiaH, DavidsonBL. Intracellular trafficking of CLN3, the protein underlying the childhood neurodegenerative disease, Batten disease. FEBS Lett, 2003; 4;555:351–357. DOI:10.1016/S0014-5793(03)01274-2.
6.
KatzML, ShibuyaH, LiuPC, et al.A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease). J Neurosci Res, 1999; 15;57:551–556. DOI:10.1002/(SICI)1097-4547(19990815)57:4<551::AID-JNR15>3.0.CO;2-R.
7.
MitchisonHM, BernardDJ, GreeneND, et al.Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. Neurobiol Dis, 1999; 6:321–334. DOI:10.1006/nbdi.1999.0267.
8.
BensaoulaT, ShibuyaH, KatzML, et al.Histopathologic and immunocytochemical analysis of the retina and ocular tissues in Batten disease. Ophthalmology, 2000; 107:1746–1753. DOI:DOI: 10.1016/S0161-6420(00)00264-5.
9.
SeigelGM, LoteryA, KummerA, et al.Retinal pathology and function in a Cln3 knockout mouse model of juvenile neuronal ceroid lipofuscinosis (Batten disease). Mol Cell Neurosci, 2002; 19:515–527. DOI:10.1006/mcne.2001.1099.
10.
KousiM, LehesjokiA-E, MoleSE. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat, 2012; 33:42–63. DOI:10.1002/humu.21624.
11.
de los ReyesE, DykenPR, PhillipsP, et al.Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect. J Child Neurol, 2004; 19:42–46. DOI:10.1177/08830738040190010703.
12.
JärveläI, LehtovirtaM, TikkanenR, et al.Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol Genet, 1999; 8:1091–1098. DOI:10.1093/hmg/8.6.1091.
13.
HaskellRE, CarrCJ, PearceDA, et al.Batten disease: evaluation of CLN3 mutations on protein localization and function. Hum Mol Genet, 2000; 22;9:735–744. DOI:10.1093/hmg/9.5.735.
14.
CongL, RanFA, CoxD, et al.Multiplex genome engineering using CRISPR/Cas systems. Science, 2013; 15;339:819–823. DOI:10.1126/science.1231143.
15.
JinekM, EastA, ChengA, et al.RNA-programmed genome editing in human cells. Elife, 2013; 2:e0047–1. DOI:10.7554/eLife.00471.
16.
MaliP, YangL, EsveltKM, et al.RNA-guided human genome engineering via Cas9. Science, 2013; 339:823–826. DOI:10.1126/science.1232033.
17.
RanFA, HsuPD, WrightJ, et al.Genome engineering using the CRISPR-Cas9 system. Nat Protoc, 2013; 8:2281–2308. DOI:10.1038/nprot.2013.143.
18.
ChenF, Pruett-MillerSM, DavisGD, et al.Gene editing using ssODNs with engineered endonucleases. Methods Mol Biol, 2015; 1239:251–265. DOI:10.1007/978-1-4939-1862-1_14.
19.
LinS, StaahlBT, AllaRK, et al.Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife, 2014; 15;3:e0476–6. DOI:10.7554/eLife.04766.
20.
ChuVT, WeberT, WefersB, et al.Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol, 2015; 33:543–548. DOI:10.1038/nbt.3198.
21.
RichardsonCD, RayGJ, DeWittMA, et al.Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol, 2016; 34:339–344. DOI:10.1038/nbt.3481.
22.
BurnightER, GuptaM, WileyLA, et al.Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration. Mol Ther, 2017; 25:1999–2013. DOI:10.1016/j.ymthe.2017.05.015.
23.
WileyLA, BurnightER, DrackAV, et al.Using patient-specific induced pluripotent stem cells and wild-type mice to develop a gene augmentation-based strategy to treat CLN3-associated retinal degeneration. Hum Gene Ther, 2016; 27:835–846. DOI:10.1089/hum.2016.049.
24.
WileyLA, BurnightER, DeLucaAP, et al.cGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness. Sci Rep, 2016; 6:3074–2. DOI:10.1038/srep30742.
25.
SharmaTP, WileyLA, WhitmoreSS, et al.Patient-specific induced pluripotent stem cells to evaluate the pathophysiology of TRNT1-associated retinitis pigmentosa. Stem Cell Res, 2017; 21:58–70. DOI:10.1016/j.scr.2017.03.005.
26.
HsuPD, ScottDA, WeinsteinJA, et al.DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol, 2013; 31:827–832. DOI:10.1038/nbt.2647.
27.
RanFA, CongL, YanWX, et al.In vivo genome editing using Staphylococcus aureus Cas9. Nature, 2015; 520:186–191. DOI:10.1038/nature14299.
28.
KimE, KooT, ParkSW, et al.In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat Commun, 2017; 8:1450–0. DOI:10.1038/ncomms14500.
29.
YamamotoY, MakiyamaT, HaritaT, et al.Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation. Hum Mol Genet, 2017; 26:1670–1677. DOI:10.1093/hmg/ddx073.
30.
MonteysAM, EbanksSA, KeiserMS, et al.CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther, 2017; 25:12–23. DOI:10.1016/j.ymthe.2016.11.010.
31.
LatellaMC, Di SalvoMT, CocchiarellaF, et al.In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR/Cas9 in the mouse retina. Mol Ther Nucleic Acids, 2016; 5:e38–9. DOI:10.1038/mtna.2016.92.
32.
LojewskiX, StaropoliJF, Biswas-LegrandS, et al.Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Hum Mol Genet, 2014; 15;23:2005–2022. DOI:10.1093/hmg/ddt596.
33.
KyrychenkoV, KyrychenkoS, TiburcyM, et al.Functional correction of dystrophin actin binding domain mutations by genome editing. JCI Insight, 2017; 2. DOI:10.1172/jci.insight.95918.
34.
KrishnanV, MaddoxJW, RodriguezT, et al.A role for the cystic fibrosis transmembrane conductance regulator in the nitric oxide-dependent release of Cl(–) from acidic organelles in amacrine cells. J Neurophysiol, 2017; 118:2842–2852. DOI:10.1152/jn.00511.2017.
35.
DeverDP, BakRO, ReinischA, et al.CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature, 2016; 539:384–389. DOI:10.1038/nature20134.
36.
MettanandaS, FisherCA, HayD, et al.Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia. Nat Commun, 2017; 8:42–4. DOI:10.1038/s41467-017-00479-7.
37.
DoenchJG, HartenianE, GrahamDB, et al.Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol, 2014; 32:1262–1267. DOI:10.1038/nbt.3026.
38.
DoenchJG, FusiN, SullenderM, et al.Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol, 2016; 34:184–191. DOI:10.1038/nbt.3437.
39.
HaeusslerM, SchönigK, EckertH, et al.Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol, 2016; 17:14–8. DOI:10.1186/s13059-016-1012-2.
40.
TsaiSQ, ZhengZ, NguyenNT, et al.GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol, 2015; 33:187–197. DOI:10.1038/nbt.3117.
41.
TsaiSQ, NguyenNT, Malagon-LopezJ, et al.CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat Methods, 2017; 14:607–614. DOI:10.1038/nmeth.4278.
42.
YanWX, MirzazadehR, GarneroneS, et al.BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks. Nat Commun, 2017; 8:1505–8. DOI:10.1038/ncomms15058.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
